431 related articles for article (PubMed ID: 25491744)
1. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
2. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
3. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
4. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.
Attarian S; Vallat JM; Magy L; Funalot B; Gonnaud PM; Lacour A; Péréon Y; Dubourg O; Pouget J; Micallef J; Franques J; Lefebvre MN; Ghorab K; Al-Moussawi M; Tiffreau V; Preudhomme M; Magot A; Leclair-Visonneau L; Stojkovic T; Bossi L; Lehert P; Gilbert W; Bertrand V; Mandel J; Milet A; Hajj R; Boudiaf L; Scart-Grès C; Nabirotchkin S; Guedj M; Chumakov I; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():199. PubMed ID: 25519680
[TBL] [Abstract][Full Text] [Related]
5. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
[TBL] [Abstract][Full Text] [Related]
7. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A.
Atanasoski S; Scherer SS; Nave KA; Suter U
J Neurosci Res; 2002 Feb; 67(4):443-9. PubMed ID: 11835311
[TBL] [Abstract][Full Text] [Related]
8. The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
Meyer zu Horste G; Miesbach TA; Muller JI; Fledrich R; Stassart RM; Kieseier BC; Coleman MP; Sereda MW
Neurobiol Dis; 2011 Apr; 42(1):1-8. PubMed ID: 21168501
[TBL] [Abstract][Full Text] [Related]
9. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
[TBL] [Abstract][Full Text] [Related]
10. PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models.
Zhao HT; Damle S; Ikeda-Lee K; Kuntz S; Li J; Mohan A; Kim A; Hung G; Scheideler MA; Scherer SS; Svaren J; Swayze EE; Kordasiewicz HB
J Clin Invest; 2018 Jan; 128(1):359-368. PubMed ID: 29202483
[TBL] [Abstract][Full Text] [Related]
11. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of PMP22 ameliorates myelin defects in iPSC-derived human organoid cultures of CMT1A.
Van Lent J; Vendredy L; Adriaenssens E; Da Silva Authier T; Asselbergh B; Kaji M; Weckhuysen S; Van Den Bosch L; Baets J; Timmerman V
Brain; 2023 Jul; 146(7):2885-2896. PubMed ID: 36511878
[TBL] [Abstract][Full Text] [Related]
13. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
[TBL] [Abstract][Full Text] [Related]
14. Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy.
Nobbio L; Fiorese F; Vigo T; Cilli M; Gherardi G; Grandis M; Melcangi RC; Mancardi G; Abbruzzese M; Schenone A
J Neuropathol Exp Neurol; 2009 May; 68(5):441-55. PubMed ID: 19525893
[TBL] [Abstract][Full Text] [Related]
15. PMP22 overexpression causes dysmyelination in mice.
Robaglia-Schlupp A; Pizant J; Norreel JC; Passage E; Sabéran-Djoneidi D; Ansaldi JL; Vinay L; Figarella-Branger D; Lévy N; Clarac F; Cau P; Pellissier JF; Fontés M
Brain; 2002 Oct; 125(Pt 10):2213-21. PubMed ID: 12244079
[TBL] [Abstract][Full Text] [Related]
16. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
[TBL] [Abstract][Full Text] [Related]
17. Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves.
Maier M; Berger P; Nave KA; Suter U
Mol Cell Neurosci; 2002 May; 20(1):93-109. PubMed ID: 12056842
[TBL] [Abstract][Full Text] [Related]
18. An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease.
Kinter J; Lazzati T; Schmid D; Zeis T; Erne B; Lützelschwab R; Steck AJ; Pareyson D; Peles E; Schaeren-Wiemers N
Neurobiol Dis; 2013 Jan; 49():221-31. PubMed ID: 22940629
[TBL] [Abstract][Full Text] [Related]
19. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
Sahenk Z; Nagaraja HN; McCracken BS; King WM; Freimer ML; Cedarbaum JM; Mendell JR
Neurology; 2005 Sep; 65(5):681-9. PubMed ID: 16157899
[TBL] [Abstract][Full Text] [Related]
20. Experimental Charcot-Marie-Tooth type 1A: a cDNA microarrays analysis.
Vigo T; Nobbio L; Hummelen PV; Abbruzzese M; Mancardi G; Verpoorten N; Verhoeven K; Sereda MW; Nave KA; Timmerman V; Schenone A
Mol Cell Neurosci; 2005 Apr; 28(4):703-14. PubMed ID: 15797717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
